What is contraction alkalosis caused by diuretic therapy and how is it managed?

Contraction Alkalosis from Diuretics: Pathophysiology and Management

What Is Contraction Alkalosis?

Contraction alkalosis is a metabolic alkalosis caused by diuretic-induced volume depletion and chloride loss, leading to enhanced renal bicarbonate reabsorption and elevated serum bicarbonate concentration. 1 The term "contraction alkalosis" is actually a misnomer—the primary mechanism is chloride depletion, not simply volume contraction, as chloride repletion alone corrects the alkalosis even when volume contraction persists. 2

Mechanism

• Loop and thiazide diuretics cause urinary chloride and potassium losses, activating the renin-angiotensin-aldosterone system and increasing distal sodium delivery, which drives bicarbonate retention by the kidney. 3
• Chloride depletion is the key perpetuating factor: without adequate chloride, the kidney cannot excrete bicarbonate even when alkalosis is present. 2
• Hypokalemia compounds the problem by shifting hydrogen ions intracellularly and stimulating renal acid excretion, further raising serum bicarbonate. 1, 3
• In heart failure patients, vigorous diuresis—especially combining loop diuretics with thiazides or metolazone—frequently produces both hypokalemia and contraction alkalosis. 1

---

Management Algorithm

Step 1: Reduce or Temporarily Discontinue the Diuretic

The cornerstone of treatment is reducing the diuretic dose to the minimum needed to maintain euvolemia, addressing the primary mechanism of alkalosis generation. 4

• In heart failure, avoid abrupt cessation of diuretics, as sudden withdrawal can precipitate pulmonary congestion and clinical decompensation. 4
• Instead, titrate down to the lowest effective dose that prevents fluid reaccumulation while allowing renal bicarbonate excretion. 1, 4
• Monitor daily weights and clinical volume status (jugular venous pressure, peripheral edema) to ensure diuretic reduction does not cause fluid retention. 4

Step 2: Aggressive Potassium Chloride Repletion

Administer potassium chloride (KCl) to achieve a serum potassium of 4.5–5.0 mEq/L in heart failure patients or 4.0–5.0 mmol/L in stable outpatients, thereby preventing arrhythmias and halting perpetuation of alkalosis. 1, 4

• Use only chloride-containing potassium salts (KCl)—non-chloride potassium salts (e.g., potassium citrate, potassium gluconate) do not provide the chloride needed for renal bicarbonate excretion. 4
• Dosing: Give oral KCl 20–60 mEq/day in divided doses for outpatients; use intravenous KCl (20–30 mEq/L added to IV fluids) when oral intake is insufficient. 1, 4
• Chloride repletion is essential: chloride depletion is the primary reason the kidney maintains alkalosis, and correcting it allows bicarbonate excretion even if volume contraction persists. 2

Step 3: Consider Potassium-Sparing Diuretics

Aldosterone antagonists (spironolactone, eplerenone) or other potassium-sparing agents (amiloride, triamterene) prevent both hypokalemia and contraction alkalosis when incorporated into the diuretic regimen. 1

• In heart failure, spironolactone 12.5–25 mg once daily (maximum 50 mg) is recommended as part of guideline-directed medical therapy. 5
• Caution: Avoid dangerous hyperkalemia when combining ACE inhibitors or ARBs with potassium-sparing agents or large doses of oral potassium. 1
• Monitor serum potassium closely, especially during the first weeks of treatment. 5, 1

Step 4: Acetazolamide for Refractory Cases

If metabolic alkalosis persists despite optimal KCl repletion and diuretic adjustment, consider acetazolamide 250–500 mg orally or intravenously once daily. 4

• Acetazolamide is a carbonic anhydrase inhibitor that enhances renal bicarbonate excretion. 6, 7
• Important: Increase KCl supplementation when using acetazolamide, as it promotes urinary potassium loss and can aggravate hypokalemia. 4
• Acetazolamide is particularly useful in severe cases where rapid correction is needed. 6, 7

Step 5: Monitoring Targets

Check serum electrolytes (Na⁺, K⁺, Cl⁻, HCO₃⁻) every 4–6 hours during active treatment, then weekly once stable. 4

• Therapeutic endpoints: Aim for bicarbonate < 26 mmol/L and arterial pH < 7.43. 4
• Monitor serum creatinine to detect declining renal function, which can complicate management. 4
• Watch for clinical signs of hypokalemia (muscle weakness, arrhythmias, cramping) even after correction of alkalosis. 4
• Frequent monitoring is especially critical during the first weeks of diuretic therapy, when complications are most common. 5

---

Special Considerations by Patient Population

Heart Failure Patients

• Optimal diuretic use is the cornerstone of successful heart failure management: inappropriately high doses lead to volume contraction, hypotension, and renal insufficiency, while inappropriately low doses cause fluid retention. 5
• Implement modest sodium restriction and daily weight monitoring to enable lower, safer diuretic doses and prevent recurrence. 4
• Diuretics should be combined with ACE inhibitors, beta-blockers, and aldosterone antagonists for long-term stability. 5

Cirrhosis Patients with Ascites

• Patients with cirrhosis are highly susceptible to rapid extracellular fluid volume reduction with loop diuretics, making contraction alkalosis particularly common. 1
• Loop diuretics cause potassium and magnesium depletion, compounding alkalosis and increasing risk of hepatic encephalopathy. 1
• Diuretic dosage should achieve weight loss no greater than 0.5 kg/day without peripheral edema or 1 kg/day with edema, to prevent diuretic-induced renal failure and hyponatremia. 5
• Hyponatremia is a frequent complication; most experts agree diuretics should be stopped temporarily if serum sodium decreases below 120–125 mmol/L. 5

---

Fluid Management Considerations

Do not use balanced crystalloids (e.g., Lactated Ringer's, Plasmalyte) as the primary fluid, as their chloride concentration (~109 mEq/L) is insufficient to correct the chloride deficit. 4

• Isotonic saline (0.9% NaCl) may be used when significant volume depletion coexists, though it is rarely required in hemodynamically stable patients. 4
• In most stable outpatients, oral KCl and diuretic dose reduction are sufficient without intravenous fluids. 4

---

Severe or Refractory Cases

For patients requiring rapid correction or those who cannot tolerate conventional therapy:

• Intravenous hydrochloric acid (0.1–0.2 N HCl) may be given through a central venous catheter for direct titration of base excess. 6, 3
• Ammonium chloride is an alternative mineral acid, but it requires hepatic conversion and should be avoided in patients with hepatic or severe renal dysfunction. 6
• Low-bicarbonate dialysis is an option if metabolic alkalosis is accompanied by kidney failure. 7, 3

---

Common Pitfalls to Avoid

• Do not use non-chloride potassium salts (e.g., potassium citrate)—they will not correct the chloride deficit driving the alkalosis. 4
• Do not abruptly stop diuretics in heart failure patients—taper the dose while monitoring volume status closely. 4
• Do not overlook magnesium depletion, which often accompanies hypokalemia and impairs potassium repletion. 1
• Do not combine potassium-sparing diuretics with ACE inhibitors/ARBs without close potassium monitoring—hyperkalemia can be life-threatening. 1
• Excessive concern about mild hypotension or azotemia can lead to underutilization of diuretics and refractory edema; continue diuresis until fluid retention is eliminated as long as the patient remains asymptomatic. 5